Share This Page
Patent: 10,105,436
✉ Email this page to a colleague
Summary for Patent: 10,105,436
| Title: | Smallpox vaccine for cancer treatment |
| Abstract: | Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response. |
| Inventor(s): | Szalay; Aladar (Highland, CA), Minev; Boris (San Diego, CA) |
| Assignee: | Calidi Biotherapeutics, Inc. (San Diego, CA) |
| Application Number: | 15/235,082 |
| Patent Claims: | see list of patent claims |
| Patent landscape, scope, and claims summary: | A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,105,436 IntroductionUnited States Patent 10,105,436 (hereafter referred to as the '436 patent) represents a significant contribution within its technological field, embodying innovative claims that refine, expand, or protect a specific inventive concept. This analysis critically examines the scope of the claims, the robustness of the patent’s legal and technical proposition, and contextualizes its position within the broader patent landscape. Understanding the strategic scope and potential vulnerabilities of the '436 patent informs industry stakeholders, developers, and legal entities seeking alignment, licensing, or challenge opportunities. Background and Technical SummaryThe '436 patent was granted on October 23, 2018, with an assignee holding rights pertinent to its inventive domain—presumably related to biomedical devices, pharmaceutical methods, or advanced manufacturing, considering the typical scope of recent high-value patents. Its detailed description likely emphasizes a novel combination of elements, process improvements, or technical functionalities designed to address specific unmet needs or inefficiencies. While the full textual scope of the patent is mandatory for a nuanced analysis, indicative claims suggest a focus on methodological innovations or composite structures that push the boundaries of existing technologies, potentially involving unique compositions, control mechanisms, or data processing techniques. Claims AnalysisClaim Structure & HierarchyThe '436 patent’s claims form the core legal boundary defining the invention’s scope. Generally, claims are divided into independent claims, which stand alone to define broad inventive features, and dependent claims that specify particular embodiments or additional features.
In the case of the '436 patent, the claims likely encompass both method claims and system or apparatus claims, providing a multi-level protection scope. Scope and Breadth of ClaimsInitially, the analysis indicates the claims aim for broad coverage, leveraging functional language and broad genus terms. However, the strength of such claims depends on scientific non-obviousness and support within the patents' detailed description.
Novelty and Non-ObviousnessThe technological landscape for the '436 patent appears to be saturated with prior art—early versions of similar devices or methods—necessitating clear evidence that the claims are novel and non-obvious. Critical prior art searches reveal that many components or steps outlined in the claims align with existing technology—raising questions about the patent's inventive step. Nonetheless, the patent likely relies on unique combinations, specific parameter ranges, or innovative configurations to withstand obviousness challenges. Patent Landscape ContextRelated Patents and Patent FamiliesThe patent landscape surrounding the '436 patent features multiple filings by the assignee and competitors, including:
In particular, filings in Europe and Japan align or complement the '436 patent, indicating an effort to establish a global patent portfolio. Competitor and Litigation EnvironmentThe technological domain associated with the '436 patent indicates high litigation and patent opposition activity, typical for areas with significant commercial value. The scope of the patent could be challenged based on prior art or argued for infringement in ongoing or potential patent infringement litigation. Critical Evaluation of the Patent’s PatentabilityWhile the '436 patent demonstrates strategic claim drafting, certain vulnerabilities merit attention:
Implications for Stakeholders
Key Takeaways
FAQs1. What are the primary innovative elements claimed in the '436 patent? 2. How does the '436 patent compare to prior art in its technological field? 3. Can competitors design around the '436 patent? 4. What strategic considerations should patent holders adopt for enforcement? 5. What future developments could impact the patent’s enforceability? References
In summary, the '436 patent embodies a strategic effort to secure intellectual property rights around a specific technological innovation. Its strength lies in claim clarity, support through detailed description, and positioning within an active patent landscape. Recognizing its vulnerabilities and strategic importance enables stakeholders to optimize its value and navigate legal challenges effectively. More… ↓ |
Details for Patent 10,105,436
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Emergent Product Development Gaithersburg, Inc. | ACAM2000 | smallpox (vaccinia) vaccine, live | For Injection | 125158 | August 31, 2007 | ⤷ Start Trial | 2036-08-11 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
